James Healy - Natera Director
| NTRA Stock | USD 88.61 3.33 3.90% |
Director
Dr. James I. Healy M.D. PhD. is an Independent Director of the Company . He served as a member of our board of directors since November 2014. Dr. Healy was a general partner at Sofinnova Ventures, a VC firm, since 2000. Prior to Sofinnova Ventures, Dr. Healy held various positions at Sanderling Ventures, a VC firm, Bayer Healthcare Pharmaceuticals, a research based pharmaceutical company and ISTA Pharmaceuticals, Inc., a company specializing in ophthalmic pharmaceutical products. Dr. Healy is currently on the board of directors of Ascendis Pharma AS, a clinicalstage biopharmaceutical company Auris Medical Holding AG, a specialty pharmaceutical company focused on tinnitus Coherus BioSciences, Inc., a biologics platform company Edge Therapeutics, a clinicalstage biotechnology company Obseva SA, a clinicalstage biopharmaceutical company and several private companies. Previously, Dr. Healy served as a board member of Anthera Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammation and autoimmune diseases Amarin Corporation plc, a commercialstage biopharmaceutical company Durata Therapeutics, Inc., a pharmaceutical company focused on infectious and acute diseases InterMune, Inc., a biotechnology company focused on orphan fibrotic pulmonary disease KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of monoclonal antibody therapeutics Hyperion Therapeutics, Inc., a commercialstage orphan disease company and a number of private companies since 2014.
| Age | 53 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 13011 McCallen Pass, Austin, TX, United States, 78753 |
| Phone | 650 980 9190 |
| Web | https://www.natera.com |
Natera Management Efficiency
The company has return on total asset (ROA) of (0.1967) % which means that it has lost $0.1967 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5911) %, meaning that it created substantial loss on money invested by shareholders. Natera's management efficiency ratios could be used to measure how well Natera manages its routine affairs as well as how well it operates its assets and liabilities. As of April 23, 2024, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.41. At present, Natera's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 208.5 M, whereas Other Assets are forecasted to decline to about 11.3 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Samir Kaul | Guardant Health | 44 | |
| David Walt | Illumina | 62 | |
| Daniel Bradbury | Illumina | 56 | |
| Hakan Bjorklund | Qiagen NV | 61 | |
| Hila Karah | DarioHealth Corp | 47 | |
| Bruce Crowther | NeoGenomics | 66 | |
| Rami Yehudiha | DarioHealth Corp | 46 | |
| Richard Crowder | Neogen | 56 | |
| Yalon Farhi | DarioHealth Corp | 54 | |
| Fred Cohen | Caredx Inc | 61 | |
| William Boehm | Neogen | 70 | |
| Katherine Napier | EXACT Sciences | 59 | |
| Rebecca Chambers | Illumina | N/A | |
| Francis deSouza | Illumina | 53 | |
| Nelson Chan | Twist Bioscience Corp | 57 | |
| Sally Agersborg | NeoGenomics | N/A | |
| Maneesh Arora | EXACT Sciences | 47 | |
| Kieran Murphy | NeoGenomics | N/A | |
| John Thompson | Illumina | 68 | |
| Fernando LpezDaz | NeoGenomics | N/A | |
| Sally Crawford | EXACT Sciences | 61 | |
Management Performance
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.2 |
Natera Inc Leadership Team
Elected by the shareholders, the Natera's board of directors comprises two types of representatives: Natera inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Natera. The board's role is to monitor Natera's management team and ensure that shareholders' interests are well served. Natera's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Natera's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steve Chapman, Senior Vice President - Commercial Operations | ||
| Michael MBA, Chief Officer | ||
| Margaret Miller, Vice President - Finance | ||
| Paul Billings, Chief Medical Officer and Senior Vice-President of Medical Affairs | ||
| Jonathan MEng, CoFounder Director | ||
| John Fesko, President Officer | ||
| Roy Baynes, Director | ||
| Robert Schueren, Chief Officer | ||
| Edward Driscoll, Director | ||
| Daniel LLM, Secretary Officer | ||
| Michael Little, Senior Vice President - Research and Development | ||
| Michael Brophy, CFO | ||
| Jerry Diffley, Chief Officer | ||
| John Steuart, Director | ||
| James Healy, Director | ||
| Jonathan Sheena, Co-Founder, CTO, Director | ||
| Roelof Botha, Lead Independent Director | ||
| Olesya CPA, Chief Officer | ||
| Gail Marcus, Independent Director | ||
| LLM LLM, S Officer | ||
| Rishi Kacker, Chief Officer | ||
| Phil Grinnell, VP Sales | ||
| Steven Chapman, CEO Director | ||
| Todd Cozzens, Director | ||
| Eric Evans, Chief Officer | ||
| Herman Rosenman, CFO | ||
| Matthew Rabinowitz, Co-Founder, Chairman, CEO and Pres |
Natera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Natera a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.40) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 9.86 B | ||||
| Shares Outstanding | 120.76 M | ||||
| Shares Owned By Insiders | 4.02 % | ||||
| Shares Owned By Institutions | 96.57 % | ||||
| Number Of Shares Shorted | 6.25 M | ||||
| Price To Earning | (4.74) X |
Natera Investors Sentiment
The influence of Natera's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Natera. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Natera's public news can be used to forecast risks associated with an investment in Natera. The trend in average sentiment can be used to explain how an investor holding Natera can time the market purely based on public headlines and social activities around Natera Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Natera's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Natera's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Natera's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Natera.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Natera in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Natera's short interest history, or implied volatility extrapolated from Natera options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Natera Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Natera Stock analysis
When running Natera's price analysis, check to measure Natera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Natera is operating at the current time. Most of Natera's value examination focuses on studying past and present price action to predict the probability of Natera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Natera's price. Additionally, you may evaluate how the addition of Natera to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Natera's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Natera. If investors know Natera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Natera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.78) | Revenue Per Share 9.414 | Quarterly Revenue Growth 0.432 | Return On Assets (0.20) | Return On Equity (0.59) |
The market value of Natera Inc is measured differently than its book value, which is the value of Natera that is recorded on the company's balance sheet. Investors also form their own opinion of Natera's value that differs from its market value or its book value, called intrinsic value, which is Natera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Natera's market value can be influenced by many factors that don't directly affect Natera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Natera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Natera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Natera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.